130 related articles for article (PubMed ID: 31693876)
21. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2004 Dec; 12(6):1155-62. PubMed ID: 15547731
[TBL] [Abstract][Full Text] [Related]
22. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
[TBL] [Abstract][Full Text] [Related]
23. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
24. Pirfenidone inhibits TGF-β1-induced metabolic reprogramming during epithelial-mesenchymal transition in non-small cell lung cancer.
Zhang S; Wang Y; Luo D; Cheng Z; Zeng Q; Wang G; Chen M; Zhang S; Luo P
J Cell Mol Med; 2024 Feb; 28(3):e18059. PubMed ID: 38140828
[TBL] [Abstract][Full Text] [Related]
25. Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling.
Lin CH; Lin HH; Kuo CY; Kao SH
Oncotarget; 2017 Feb; 8(7):11316-11328. PubMed ID: 28076322
[TBL] [Abstract][Full Text] [Related]
26. (-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
Shin S; Kim MK; Jung W; Chong Y
Phytother Res; 2018 Oct; 32(10):2086-2096. PubMed ID: 30009577
[TBL] [Abstract][Full Text] [Related]
27. Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.
Li C; Rezov V; Joensuu E; Vartiainen V; Rönty M; Yin M; Myllärniemi M; Koli K
Sci Rep; 2018 Jul; 8(1):10070. PubMed ID: 29968778
[TBL] [Abstract][Full Text] [Related]
28. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
29. Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro.
Shetty S; Idell S
Am J Physiol Lung Cell Mol Physiol; 2000 Jan; 278(1):L148-56. PubMed ID: 10645902
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Mashiko S; Kitatani K; Toyoshima M; Ichimura A; Dan T; Usui T; Ishibashi M; Shigeta S; Nagase S; Miyata T; Yaegashi N
Cancer Biol Ther; 2015; 16(2):253-60. PubMed ID: 25587663
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
32. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Peng PL; Hsieh YS; Wang CJ; Hsu JL; Chou FP
Toxicol Appl Pharmacol; 2006 Jul; 214(1):8-15. PubMed ID: 16387334
[TBL] [Abstract][Full Text] [Related]
34. Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle Arrest.
Usugi E; Ishii K; Hirokawa Y; Kanayama K; Matsuda C; Uchida K; Shiraishi T; Watanabe M
Pharmacology; 2019; 103(5-6):250-256. PubMed ID: 30731453
[TBL] [Abstract][Full Text] [Related]
35. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor.
Degryse B; Sier CF; Resnati M; Conese M; Blasi F
FEBS Lett; 2001 Sep; 505(2):249-54. PubMed ID: 11566185
[TBL] [Abstract][Full Text] [Related]
36. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Arnoletti JP; Albo D; Granick MS; Solomon MP; Castiglioni A; Rothman VL; Tuszynski GP
Cancer; 1995 Sep; 76(6):998-1005. PubMed ID: 8625226
[TBL] [Abstract][Full Text] [Related]
37. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
38. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro.
Brooks TD; Wang SW; Brünner N; Charlton PA
Anticancer Drugs; 2004 Jan; 15(1):37-44. PubMed ID: 15090742
[TBL] [Abstract][Full Text] [Related]
39. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Gershtein ES; Kushlinskii NE
Bull Exp Biol Med; 2001 Jan; 131(1):67-72. PubMed ID: 11329087
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression.
Lee H; Struman I; Clapp C; Martial J; Weiner RI
Endocrinology; 1998 Sep; 139(9):3696-703. PubMed ID: 9724020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
